Used as main image by Phynd in search results and profile page

Joseph I Clark, MD

Medical Oncology, Hematology & Oncology, Internal Medicine

Provider Groups

  • Loyola Medicine Physician

  • Loyola Physician Partners

Primary Contact

888-584-7888
Provider Groups
  • Loyola Medicine Physician

  • Loyola Physician Partners

Primary Contact
888-584-7888

Services & Specialties

Areas of Specialization

  • Hematology & Oncology
  • Internal Medicine
  • Medical Oncology

Locations & Contact

Primary Location

Loyola University Medical Center

2160 S First Ave
Maywood , IL 60153

View hours
Tuesday
8:00am - 5:00pm
Monday
8:00am - 5:00pm
Wednesday
8:00am - 5:00pm
Thursday
8:00am - 5:00pm
Friday
8:00am - 5:00pm
Saturday
8:00am - 5:00pm
Sunday
8:00am - 5:00pm
Loyola University Medical Center

About

I am a medical oncologist here at Loyola with a particular clinical and research interest in the treatment of patients with malignant melanoma, and other skin cancers, kidney cancer, head and neck cancer, salivary gland cancers, and thyroid cancers. I work closely with our surgical oncology and our radiation oncology colleagues to offer the best possible treatment options available to each individual patient. I take a caring approach to all those I treat as if they were my own family member.

Academic Title

Professor

Leadership Title

Regional Director - Oncology Service Line
Division Director, Hematology - Oncology

Ages Seen

Adults - Over 65
Adults - 18 to 64

Procedures Performed

  • cancer

Additional Resources

Education & Certifications

Education

Education:
University of Illinois at Urbana-Champaign (1984)

Education:
Loyola University Stritch School of Medicine (1989)

Residency:
Loyola University Medical Center (1992)

Fellowship:
Fox Chase Cancer Center (1995)

Board Certifications

Medical Oncology, Medical Oncology, American Board of Internal Medicine Subspecialty (1995)

Provider Groups

Loyola Medicine Physician

Loyola Physician Partners

Provider Ratings

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn More >

4.9 out of 5

(130 ratings)

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

35 Reviews

07/23/2024

Was very thorough and kind

07/16/2024

Compassionate

07/15/2024

Dr Clark is very friendly and professional

07/02/2024

To the point explanations.

07/02/2024

ALL CARE WAS EXECELLENT

05/06/2024

Very professional and courteous thankyou thankyou thankyou !!!

04/30/2024

As well as could be expected

04/29/2024

If I ever need an oncologist in the future after next year, I will want Dr. Clark.

04/29/2024

There all great

03/26/2024

14 years with Dr. Clark. I trust him with my life.

03/19/2024

Appointments have been on-schedule, thank you

03/12/2024

Hes caring and has concern fr his patients

02/28/2024

Excellent caring doctor

02/19/2024

Very pleased with hospital and staff

02/14/2024

I would recommend Dr. Clark anytime

01/30/2024

He is professional, friendly and an excellent physician. A

12/20/2023

All great

12/13/2023

He help save my life. I am quite pleased all in all with the help that and care that I was given.

12/13/2023

i'm not laying it on thick, Loyola is really that good !

12/12/2023

Thanks for caring about condition and professionally responding to concerns

12/11/2023

Dr. Clark and his nursing staff are true professionals and coaches

11/01/2023

I’ve been seeing Dr Clark for 16 years, wouldn’t want to change to anyone else!

10/19/2023

He treats me like a real human being not just doing his job he shows me that he cares.

10/18/2023

Honest Dr

10/05/2023

Excelente atención

10/02/2023

A+ across the board

09/25/2023

Dr. Clark is always timely, attentive and helpful.

09/05/2023

The care I received was excellent. I felt everyone who rendered care was knowledgeable and concerned for my well-being.

08/31/2023

Dr clarks il-2 treatment 20 years ago gave me 20 years of remission which i deeply appreciated.

08/24/2023

Sincere and helpful

08/23/2023

Very happy with all the doctors and staff at Loyola Hospital

08/04/2023

Speechless

07/07/2023

no comment

07/06/2023

I'm looking forward to my next visit

06/30/2023

Use Dr Clark as an example to what all your providers should be. Loyola has lost some excellent docs two that I have had wish I still had the replacements are not of the same caliber
Show more

Publications

  • Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial. Lara, P. N.; Tangen, C.; Heath, E. I.; Gulati, S.; Stein, M. N.; Meng, M.; Alva, A. S.; Pal, S. K.; Puzanov, I.; Clark, J. I.; Choueiri, T. K.; Agarwal, N.; Uzzo, R.; Haas, N. B.; Synold, T. W.; Plets, M.; Vaishampayan, U. N.; Shuch, B. M.; Lerner, S.; Thompson, I. M.; Ryan, C. W.; European urology
  • Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. Ryan, C. W.; Tangen, C. M.; Heath, E. I.; Stein, M. N.; Meng, M. V.; Alva, A. S.; Pal, S. K.; Puzanov, I.; Clark, J. I.; Choueiri, T. K.; Agarwal, N.; Uzzo, R. G.; Haas, N. B.; Synold, T. W.; Plets, M.; Vaishampayan, U. N.; Shuch, B. M.; Thompson, I. M.; Lara, P. N.; Lancet (London, England)
  • Implementing a cognitive behavioral intervention for patients with head and neck cancer. Thilges, S.; Mumby, P.; Sinacore, J.; Clark, J.; Czerlanis, C.; Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary Perspective. Abou Elkassem, A. M.; Lo, S. S.; Gunn, A. J.; Shuch, B. M.; Dewitt-Foy, M. E.; Abouassaly, R.; Vaidya, S. S.; Clark, J. I.; Louie, A. V.; Siva, S.; Grosu, A. L.; Smith, A. D.; Radiographics : a review publication of the Radiological Society of North America, Inc
  • HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells. Moore, T. V.; Scurti, G. M.; DeJong, M.; Wang, S. Y.; Dalheim, A. V.; Wagner, C. R.; Hutchens, K. A.; Speiser, J. J.; Godellas, C. V.; Fountain, C.; Fleser, J.; Moudgil, T.; Thomas, M.; Murray, D.; Curti, B. D.; Clark, J. I.; Fox, B. A.; Nishimura, M. I.; Molecular therapy oncolytics
  • Cytoreductive Nephrectomy for Synchronous Metastatic Renal Cell Carcinoma-Are There Any Favorable Risk Patients? Patel, H. D.; Clark, J. I.; Flanigan, R. C.; The Journal of urology
  • Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2. Clark, J. I.; Curti, B.; Davis, E. J.; Kaufman, H.; Amin, A.; Alva, A.; Logan, T. F.; Hauke, R.; Miletello, G. P.; Vaishampayan, U.; Johnson, D. B.; White, R. L.; Wiernik, P. H.; Dutcher, J. P.; Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  • Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Algazi, A. P.; Othus, M.; Daud, A. I.; Lo, R. S.; Mehnert, J. M.; Truong, T. G.; Conry, R.; Kendra, K.; Doolittle, G. C.; Clark, J. I.; Messino, M. J.; Moore, D. F.; Lao, C.; Faller, B. A.; Govindarajan, R.; Harker-Murray, A.; Dreisbach, L.; Moon, J.; Grossmann, K. F.; Ribas, A.; Nature medicine
  • High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. Silk, A. W.; Kaufman, H. L.; Curti, B.; Mehnert, J. M.; Margolin, K.; McDermott, D.; Clark, J.; Newman, J.; Bommareddy, P. K.; Denzin, L.; Najmi, S.; Haider, A.; Shih, W.; Kane, M. P.; Zloza, A.; Frontiers in oncology
  • Combined radio-immunotherapy leads to complete clinical regression of stage IV Merkel cell carcinoma. Principe, D. R.; Clark, J. I.; Emami, B.; Borowicz, S.; BMJ case reports
  • Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry. Fishman, M.; Dutcher, J. P.; Clark, J. I.; Alva, A.; Miletello, G. P.; Curti, B.; Agarwal, N.; Hauke, R.; Mahoney, K. M.; Moon, H.; Treisman, J.; Tykodi, S. S.; Daniels, G.; Morse, M. A.; Wong, M. K. K.; Kaufman, H.; Gregory, N.; McDermott, D. F.; Journal for immunotherapy of cancer
  • Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. Buchbinder, E. I.; Dutcher, J. P.; Daniels, G. A.; Curti, B. D.; Patel, S. P.; Holtan, S. G.; Miletello, G. P.; Fishman, M. N.; Gonzalez, R.; Clark, J. I.; Richart, J. M.; Lao, C. D.; Tykodi, S. S.; Silk, A. W.; McDermott, D. F.; Journal for immunotherapy of cancer
  • Sunitinib and Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. Bajic, P.; Flanigan, R. C.; Joyce, C. J.; Clark, J. I.; The Journal of urology
  • A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma. Clark, J. I.; Singh, J.; Ernstoff, M. S.; Lao, C. D.; Flaherty, L. E.; Logan, T. F.; Curti, B.; Agarwala, S. S.; Taback, B.; Cranmer, L.; Lutzky, J.; Luna, T. L.; Aung, S.; Lawson, D. H.; Journal for immunotherapy of cancer
  • Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report. Clark, J. I.; Bufalino, S.; Singh, S.; Borys, E.; Journal for immunotherapy of cancer
  • An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. Sullivan, R. J.; Atkins, M. B.; Kirkwood, J. M.; Agarwala, S. S.; Clark, J. I.; Ernstoff, M. S.; Fecher, L.; Gajewski, T. F.; Gastman, B.; Lawson, D. H.; Lutzky, J.; McDermott, D. F.; Margolin, K. A.; Mehnert, J. M.; Pavlick, A. C.; Richards, J. M.; Rubin, K. M.; Sharfman, W.; Silverstein, S.; Slingluff, C. L.; Sondak, V. K.; Tarhini, A. A.; Thompson, J. A.; Urba, W. J.; White, R. L.; Whitman, E. D.; Hodi, F. S.; Kaufman, H. L.; Journal for immunotherapy of cancer
  • Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. Moore, T.; Wagner, C. R.; Scurti, G. M.; Hutchens, K. A.; Godellas, C.; Clark, A. L.; Kolawole, E. M.; Hellman, L. M.; Singh, N. K.; Huyke, F. A.; Wang, S. Y.; Calabrese, K. M.; Embree, H. D.; Orentas, R.; Shirai, K.; Dellacecca, E.; Garrett-Mayer, E.; Li, M.; Eby, J. M.; Stiff, P. J.; Evavold, B. D.; Baker, B. M.; Le Poole, I. C.; Dropulic, B.; Clark, J. I.; Nishimura, M. I.; Cancer immunology, immunotherapy : CII
  • Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. Curti, B.; Daniels, G. A.; McDermott, D. F.; Clark, J. I.; Kaufman, H. L.; Logan, T. F.; Singh, J.; Kaur, M.; Luna, T. L.; Gregory, N.; Morse, M. A.; Wong, M. K. K.; Dutcher, J. P.; Journal for immunotherapy of cancer
  • Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. Moore, T.; Wagner, C. R.; Scurti, G. M.; Hutchens, K. A.; Godellas, C.; Clark, A. L.; Kolawole, E. M.; Hellman, L. M.; Singh, N. K.; Huyke, F. A.; Wang, S. Y.; Calabrese, K. M.; Embree, H. D.; Orentas, R.; Shirai, K.; Dellacecca, E.; Garrett-Mayer, E.; Li, M.; Eby, J. M.; Stiff, P. J.; Evavold, B. D.; Baker, B. M.; Le Poole, I. C.; Dropulic, B.; Clark, J. I.; Nishimura, M. I.; Cancer immunology, immunotherapy : CII
  • Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Atkins, M. B.; Clark, J. I.; Quinn, D. I.; Annals of oncology : official journal of the European Society for Medical Oncology
  • Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. Clark, J. I.; Wong, M. K. K.; Kaufman, H. L.; Daniels, G. A.; Morse, M. A.; McDermott, D. F.; Agarwala, S. S.; Lewis, L. D.; Stewart, J. H.; Vaishampayan, U.; Curti, B.; Gonzalez, R.; Lutzky, J.; Rudraptna, V.; Cranmer, L. D.; Jeter, J. M.; Hauke, R. J.; Miletello, G.; Milhem, M. M.; Amin, A.; Richart, J. M.; Fishman, M.; Hallmeyer, S.; Patel, S. P.; Van Veldhuizen, P.; Agarwal, N.; Taback, B.; Treisman, J. S.; Ernstoff, M. S.; Perritt, J. C.; Hua, H.; Rao, T. B.; Dutcher, J. P.; Aung, S.; Clinical genitourinary cancer
  • Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma. Klarquist, J.; Tobin, K.; Farhangi Oskuei, P.; Henning, S. W.; Fernandez, M. F.; Dellacecca, E. R.; Navarro, F. C.; Eby, J. M.; Chatterjee, S.; Mehrotra, S.; Clark, J. I.; Le Poole, I. C.; Cancer research
  • Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Alva, A.; Daniels, G. A.; Wong, M. K.; Kaufman, H. L.; Morse, M. A.; McDermott, D. F.; Clark, J. I.; Agarwala, S. S.; Miletello, G.; Logan, T. F.; Hauke, R. J.; Curti, B.; Kirkwood, J. M.; Gonzalez, R.; Amin, A.; Fishman, M.; Agarwal, N.; Lowder, J. N.; Hua, H.; Aung, S.; Dutcher, J. P.; Cancer immunology, immunotherapy : CII
  • A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. Buchbinder, E. I.; Gunturi, A.; Perritt, J.; Dutcher, J.; Aung, S.; Kaufman, H. L.; Ernstoff, M. S.; Miletello, G. P.; Curti, B. D.; Daniels, G. A.; Patel, S. P.; Kirkwood, J. M.; Hallmeyer, S.; Clark, J. I.; Gonzalez, R.; Richart, J. M.; Lutzky, J.; Morse, M. A.; Sullivan, R. J.; McDermott, D. F.; Journal for immunotherapy of cancer
  • Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. Johnson, D. B.; Sullivan, R. J.; Ott, P. A.; Carlino, M. S.; Khushalani, N. I.; Ye, F.; Guminski, A.; Puzanov, I.; Lawrence, D. P.; Buchbinder, E. I.; Mudigonda, T.; Spencer, K.; Bender, C.; Lee, J.; Kaufman, H. L.; Menzies, A. M.; Hassel, J. C.; Mehnert, J. M.; Sosman, J. A.; Long, G. V.; Clark, J. I.; JAMA oncology
  • Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face. Block, A. M.; Alite, F.; Diaz, A. Z.; Borrowdale, R. W.; Clark, J. I.; Choi, M.; Case reports in oncological medicine
  • Robust Differences in p16-Dependent Oropharyngeal Squamous Cell Carcinoma Distant Metastasis: Implications for Targeted Therapy. Jaber, J. J.; Murrill, L.; Clark, J. I.; Johnson, J. T.; Feustel, P. J.; Mehta, V.; Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • Multidisciplinary treatment of olfactory neuroblastoma: Patterns of failure and management of recurrence. Petruzzelli, G. J.; Howell, J. B.; Pederson, A.; Origitano, T. C.; Byrne, R. W.; Munoz, L.; Emami, B.; Clark, J. I.; American journal of otolaryngology
  • Ipilimumab for the treatment of melanoma. Jain, S.; Clark, J. I.; Melanoma management
  • The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. McDermott, D. F.; Cheng, S. C.; Signoretti, S.; Margolin, K. A.; Clark, J. I.; Sosman, J. A.; Dutcher, J. P.; Logan, T. F.; Curti, B. D.; Ernstoff, M. S.; Appleman, L.; Wong, M. K.; Khushalani, N. I.; Oleksowicz, L.; Vaishampayan, U. N.; Mier, J. W.; Panka, D. J.; Bhatt, R. S.; Bailey, A. S.; Leibovich, B. C.; Kwon, E. D.; Kabbinavar, F. F.; Belldegrun, A. S.; Figlin, R. A.; Pantuck, A. J.; Regan, M. M.; Atkins, M. B.; Clinical cancer research : an official journal of the American Association for Cancer Research
  • Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Escudier, B.; Michaelson, M. D.; Motzer, R. J.; Hutson, T. E.; Clark, J. I.; Lim, H. Y.; Porfiri, E.; Zalewski, P.; Kannourakis, G.; Staehler, M.; Tarazi, J.; Rosbrook, B.; Cisar, L.; Hariharan, S.; Kim, S.; Rini, B. I.; British journal of cancer
  • A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. Dandamudi, U. B.; Ghebremichael, M.; Sosman, J. A.; Clark, J. I.; McDermott, D. F.; Atkins, M. B.; Dutcher, J. P.; Urba, W. J.; Regan, M. M.; Puzanov, I.; Crocenzi, T. S.; Curti, B. D.; Vaishampayan, U. N.; Crosby, N. A.; Margolin, K. A.; Ernstoff, M. S.; Journal of immunotherapy (Hagerstown, Md. : 1997)
  • Evolving treatment strategies in thin cutaneous head and neck melanoma: 1 institution's experience. Jaber, J. J.; Clark, J. I.; Muzaffar, K.; Ruggiero, F. P.; Feustel, P. J.; Frett, M. J.; Zender, C. A.; Head & neck
  • Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Clark, J. I.; Moon, J.; Hutchins, L. F.; Sosman, J. A.; Kast, W. M.; Da Silva, D. M.; Liu, P. Y.; Thompson, J. A.; Flaherty, L. E.; Sondak, V. K.; Cancer
  • Phase I adjuvant radiation with docetaxel in high-risk head and neck cancer. Clark, J. I.; Eisner, R. M.; Hofmeister, C.; Norton, J.; Thomas, S.; Choudhury, A.; Petruzzelli, G.; Lathers, D.; Young, M. R.; Lau, A.; Emami, B.; American journal of clinical oncology
  • Clinicopathological review: esthesioneuroblastoma. Bragg, T. M.; Scianna, J.; Kassam, A.; Emami, B.; Brown, H. G.; Hacein-Bey, L.; Clark, J. I.; Muzaffar, K.; Boulis, N.; Prabhu, V. C.; Neurosurgery
  • Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study. Clark, J. I.; Mehrabi, J.; Sosman, J. A.; Logan, T. F.; Margolin, K. A.; Dutcher, J. P.; Urba, W. J.; Ernstoff, M. S.; McDermott, D. F.; Lau, A. M.; Atkins, M. B.; Journal of immunotherapy (Hagerstown, Md. : 1997)
  • Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults. Meyer, P. N.; Clark, J. I.; Flanigan, R. C.; Picken, M. M.; American journal of clinical pathology
  • Passive seeding in metanephric adenoma: a review of pseudometastatic lesions in perinephric lymph nodes. Paner, G. P.; Turk, T. M.; Clark, J. I.; Lindgren, V.; Picken, M. M.; Archives of pathology & laboratory medicine
  • Review. Farray, D.; Clark, J. I.; Clinical advances in hematology & oncology : H&O
  • Neoadjuvant therapy: an emerging concept in oncology. Tanvetyanon, T.; Clark, J. I.; Campbell, S. C.; Lo, S. S.; Southern medical journal
  • Case report and brief review: IL-2-induced myocarditis. Eisner, R. M.; Husain, A.; Clark, J. I.; Cancer investigation
  • Metastatic juxtaglomerular cell tumor in a 52-year-old man. Duan, X.; Bruneval, P.; Hammadeh, R.; Fresco, R.; Eble, J. N.; Clark, J. I.; Vigneswaran, W. T.; Flanigan, R. C.; Picken, M. M.; The American journal of surgical pathology
  • Posterior marginal mandibulectomy in the management of cancer of the oral cavity and oropharynx. Petruzzelli, G. J.; Knight, F. K.; Vandevender, D.; Clark, J. I.; Emami, B.; Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • Metastatic renal cell carcinoma. Flanigan, R. C.; Campbell, S. C.; Clark, J. I.; Picken, M. M.; Current treatment options in oncology
  • Nephrectomy in metastatic renal cell carcinoma. Campbell, S. C.; Flanigan, R. C.; Clark, J. I.; Current treatment options in oncology
  • Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. Clark, J. I.; Atkins, M. B.; Urba, W. J.; Creech, S.; Figlin, R. A.; Dutcher, J. P.; Flaherty, L.; Sosman, J. A.; Logan, T. F.; White, R.; Weiss, G. R.; Redman, B. G.; Tretter, C. P.; McDermott, D.; Smith, J. W.; Gordon, M. S.; Margolin, K. A.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Naeem, M.; Dahiya, M.; Clark, J. I.; Creech, S. D.; Alkan, S.; Human pathology
  • Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. Albain, K. S.; Crowley, J. J.; Turrisi, A. T.; Gandara, D. R.; Farrar, W. B.; Clark, J. I.; Beasley, K. R.; Livingston, R. B.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Response to paclitaxel and carboplatin in metastatic salivary gland cancer: a case report. Ruzich, J. C.; Ciesla, M. C.; Clark, J. I.; Head & neck
  • Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. Clark, J. I.; Hofmeister, C.; Choudhury, A.; Matz, G.; Collins, S.; Bastian, R.; Melian, E.; Emami, B.; Petruzzelli, G.; Cancer
  • Metanephric adenosarcoma in a young adult: morphologic, immunophenotypic, ultrastructural, and fluorescence in situ hybridization analyses: a case report and review of the literature. Picken, M. M.; Curry, J. L.; Lindgren, V.; Clark, J. I.; Eble, J. N.; The American journal of surgical pathology
  • Combined modality therapy for early stage operable and locally advanced potentially resectable non-small cell lung carcinoma. Clark, J. I.; Albain, K. S.; Cancer treatment and research
  • Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Nikitina, E. Y.; Clark, J. I.; Van Beynen, J.; Chada, S.; Virmani, A. K.; Carbone, D. P.; Gabrilovich, D. I.; Clinical cancer research : an official journal of the American Association for Cancer Research
  • Role of cytokines in pathology of melanoma and use of biologic response modifiers in melanoma. Clark, J. I.; Methods in molecular medicine
  • New therapeutic strategies for the treatment and prevention of head and neck cancer. Lingen, M. W.; Emami, B.; Clark, J. I.; Expert opinion on investigational drugs